Evommune Q2 Update: AD Data in September, Cash Through 2028
EVMN sits 25% above its 52-week low of $10.47.
Summary
Evommune reported Q2 2026 financials and set key pipeline milestones. Top-line Phase 2b data for EVO756 in atopic dermatitis is due September 2026 — a near-term binary catalyst after the drug's CSU failure in June. The company also initiated a Phase 2b trial in migraine prophylaxis, with data in 2027, and plans to present full Phase 2a results for EVO301 in AD at a medical conference. Cash runway extends through 2028, covering multiple readouts. This follows the June 2026 EVO756 CSU miss and the July migraine trial start, adding concrete timelines and financial context.
At the time of this announcement, EVMN was trading at $13.11 on NYSE in the Life Sciences sector, with a market capitalization of approximately $481.9M. The 52-week trading range was $10.47 to $33.20. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.